Company Filing History:
Years Active: 2021-2023
Title: Onur Boyman: Innovator in Monoclonal Antibody Development
Introduction
Onur Boyman is a notable inventor based in Küsnacht, Switzerland. He has made significant contributions to the field of immunology, particularly through his work on humanized monoclonal antibodies. With a total of 3 patents, Boyman has focused on developing innovative solutions to enhance immune responses.
Latest Patents
Boyman's latest patents include groundbreaking inventions related to immune-stimulating humanized monoclonal antibodies against human interleukin-2 (hIL-2). One of his patents describes antibodies that bind to hIL-2, specifically targeting a unique epitope. This binding capability inhibits the interaction of hIL-2 with CD25, which is crucial for immune regulation. Another patent focuses on a specific monoclonal antibody that also inhibits hIL-2 binding to CD25, characterized by specific amino acid sequences and binding parameters.
Career Highlights
Throughout his career, Onur Boyman has worked with prestigious organizations such as Universität Zürich and Novartis AG. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant advancements in antibody research.
Collaborations
Some of Boyman's notable coworkers include Natalia Arenas-Ramirez and Chao Zou. Their collaborative efforts have further enhanced the research and development of innovative therapeutic solutions.
Conclusion
Onur Boyman stands out as a prominent inventor in the field of immunology, with a focus on developing monoclonal antibodies that have the potential to revolutionize treatments for various diseases. His contributions continue to impact the scientific community and pave the way for future innovations.